Safety of Buprenorphine Transdermal Patch (BTDS) in Osteoarthritis Pain: a 52-Week Extension Phase

September 5, 2012 updated by: Purdue Pharma LP

A Randomized, Double-blind, Multicenter, Active Comparator Study to Determine the Efficacy and Safety of BTDS 20 or OxyIR® Versus BTDS 5 in Subjects With Moderate to Severe Osteoarthritis (OA) Pain: A 52-Week Extension Phase

The purpose of this phase is to evaluate the long-term safety and tolerability of BTDS. Qualified subjects are started on BTDS 5 and the dose may be titrated, if necessary, to a maximum of BTDS 20 to achieve stable pain control.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

Buprenorphine is a synthetic opioid analgesic with over 25 years of international clinical experience indicating it to be safe and effective in a variety of therapeutic situations for the relief of moderate to severe pain.

Study Type

Interventional

Enrollment (Actual)

196

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Alabama
      • Alabaster, Alabama, United States, 35007
        • Alabama Neurology and Pain Medicine
      • Birmingham, Alabama, United States, 35249
        • University of Alabama Hospital
      • Birmingham, Alabama, United States, 35215
        • Research Facility
      • Birmingham, Alabama, United States, 35244
        • The Birmingham Pain Center
      • Fairfield, Alabama, United States, 35064
        • HealthSouth Metro West Hospital
    • Arizona
      • Phoenix, Arizona, United States, 85023
        • Arizona Research Center
      • Phoenix, Arizona, United States, 85029
        • Research Facility
      • Phoenix, Arizona, United States, 85018
        • Research Facility
      • Tucson, Arizona, United States, 85712
        • Research Facility
    • Arkansas
      • Hot Springs, Arkansas, United States, 71913
        • Hot Springs Pain Clinic
    • California
      • Buena Park, California, United States, 90620
        • Research Facility
      • Chula Vista, California, United States, 91911
        • Research Facility
      • Fresno, California, United States, 93720
        • Research Facility
      • Los Gatos, California, United States, 95032
        • Research Facility
      • Roseville, California, United States, 95661
        • Research Facility
      • San Diego, California, United States, 92103
        • nTouch Research Corporation
      • San Diego, California, United States, 92120
        • Research Facility
      • Torrence, California, United States, 90505
        • Research Facility
      • Upland, California, United States, 91786
        • Research Facility
    • Colorado
      • Pueblo, Colorado, United States, 81008
        • Research Facility
    • Connecticut
      • Bridgeport, Connecticut, United States, 06606
        • Research Facility
    • Florida
      • Coral Gables, Florida, United States, 33134
        • Research Facility
      • Daytona Beach, Florida, United States, 32114
        • Research Facility
      • Hialeah, Florida, United States, 33013
        • Research Facility
      • Jupiter, Florida, United States, 99458
        • Research Facility
      • Largo, Florida, United States, 33770
        • Research Facility
      • Miami, Florida, United States, 33155
        • Research Facility
      • North Miami Beach, Florida, United States, 33180
        • Research Facility
      • Ocala, Florida, United States, 34471
        • Research Facility
      • Ormond Beach, Florida, United States, 32174
        • Research Facility
      • Palm Harbor, Florida, United States, 34684
        • Research Facility
      • Pembroke Pines, Florida, United States, 33024
        • Research Facility
      • Pinellas Park, Florida, United States, 33781
        • Radiant Research
      • Plantation, Florida, United States, 33324
        • Research Facility
      • Port Orange, Florida, United States, 32127
        • Research Facility
      • Tampa, Florida, United States, 33614
        • Research Facility
      • West Palm Beach, Florida, United States, 33409
        • Research Facility
    • Georgia
      • Marietta, Georgia, United States, 30060
        • Research Facility
    • Idaho
      • Boise, Idaho, United States, 83702
        • Research Facility
      • Meridian, Idaho, United States, 83642
        • Idaho Arthritis Osteoporosis
    • Illinois
      • Chicago, Illinois, United States, 60610
        • Research Facility
      • Springfield, Illinois, United States, 62704
        • Research Facility
    • Iowa
      • West Des Moines, Iowa, United States, 50265
        • Integrated Clinical Trials
    • Kentucky
      • Louisville, Kentucky, United States, 40213
        • Louisville Endocrinology PSC
      • Madisonville, Kentucky, United States, 42431
        • Research Facility
    • Louisiana
      • New Orleans, Louisiana, United States, 70114
        • Research Facility
      • New Orleans, Louisiana, United States, 70115
        • Research Facility
      • New Orleans, Louisiana, United States, 70128
        • Dolby Providers
    • Maryland
      • Baltimore, Maryland, United States, 21215
        • Research Facility
      • Columbia, Maryland, United States, 21045
        • Patuxent Medical Group
      • Hagerstown, Maryland, United States, 21740
        • Research Facility
    • Massachusetts
      • Brockton, Massachusetts, United States, 02301
        • Research Facility
    • Michigan
      • Benzonia, Michigan, United States, 49616
        • Crystal Lake Health Center
      • Kalamazoo, Michigan, United States, 49009
        • Rheumatology Pc
      • Lansing, Michigan, United States, 48917
        • Research Facility
    • Missouri
      • Independence, Missouri, United States, 64055
        • KC Pain Centers East
      • St. Louis, Missouri, United States, 63117
        • Research Facility
      • St. Louis, Missouri, United States, 63141
        • HealthCare Research LLC
    • Nevada
      • Las Vegas, Nevada, United States, 89106
        • Research Facility
      • Las Vegas, Nevada, United States, 89117
        • Research Facility
    • New York
      • New York, New York, United States, 10021
        • Research Facility
      • Syracuse, New York, United States, 13210
        • Research Facility
    • North Carolina
      • Charlotte, North Carolina, United States, 28210
        • The Arthritis Clinic and Carolina Bone and Joint
      • Durham, North Carolina, United States, 27704
        • Triangle Orthopaedic Associates
      • Greensboro, North Carolina, United States, 27401
        • Research Facility
      • Hickory, North Carolina, United States, 28601
        • Research Facility
      • High Point, North Carolina, United States, 27262
        • Cornerstone Research Care
    • Ohio
      • Cincinnati, Ohio, United States, 45241
        • Research Facility
      • Columbus, Ohio, United States, 43235
        • Research Facility
    • Oklahoma
      • Oklahoma City, Oklahoma, United States, 73103
        • Research Facility
    • Oregon
      • Eugene, Oregon, United States, 97404
        • Research Facility
    • Pennsylvania
      • Altoona, Pennsylvania, United States, 16602
        • Research Facility
      • Duncansville, Pennsylvania, United States, 16635
        • Research Facility
      • Jenkintown, Pennsylvania, United States, 19046
        • The Clinical Trial Center
      • Mechanicsburg, Pennsylvania, United States, 17055
        • Research Facility
    • Rhode Island
      • Cranston, Rhode Island, United States, 02920
        • New England Center for Clinical Research
    • South Carolina
      • Greer, South Carolina, United States, 29651
        • Radiant Research
    • Texas
      • Amarillo, Texas, United States, 79124
        • Allergy ARTS
      • Conroe, Texas, United States, 77304
        • Research Facility
      • Corpus Christi, Texas, United States, 78411
        • Family Practice Associates
      • Dallas, Texas, United States, 75218
        • Research Facility
      • Dallas, Texas, United States, 75251
        • Research Facility
      • Houston, Texas, United States, 77054
        • Research Facility
      • Richardson, Texas, United States, 75080
        • KRK Medical Research
      • San Antonio, Texas, United States, 78217
        • Research Facility
      • San Antonio, Texas, United States, 78238
        • Research Facility
    • Washington
      • Spokane, Washington, United States, 99207
        • Research Facility
    • Wisconsin
      • Milwaukee, Wisconsin, United States, 53218
        • Research Facility
      • New Berlin, Wisconsin, United States, 53151
        • Research Facility

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Subjects who completed all visits of the double-blind phase on study drug and subjects who discontinued study drug due to lack of therapeutic effect in the double-blind phase but completed all visits of the double-blind phase off study drug are eligible to enroll in the extension phase.

Exclusion Criteria:

  • Subjects who prematurely discontinue study drug in the double-blind phase due to adverse event, subject's choice, administrative reason or lost to follow-up are NOT eligible to enter the extension phase
  • Subjects with electrocardiograms (ECGs) that show any QT data corrected for heart rate using Fridericia formula (QTcF) interval ≥ 500 millisecond (msec) will be discontinued from the extension phase.
  • Subjects requiring long-acting opioid analgesics (once- or twice-daily dosing with an every (q) 24 hour (h) or q12h drug) or transdermal fentanyl during the extension phase should be discontinued from the study.

Refer to core study for additional inclusion/exclusion information.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: BTDS
Buprenorphine transdermal patch
Drug: Buprenorphine transdermal patch
Buprenorphine transdermal patch 5 mcg/h applied transdermally for 7-day wear.
Other Names:
  • Butrans™
Drug: Buprenorphine transdermal patch
Buprenorphine transdermal patch 10 mcg/h applied transdermally for 7-day wear.
Other Names:
  • Butrans™
Drug: Buprenorphine transdermal patch
Buprenorphine transdermal patch 20 mcg/h applied transdermally for 7-day wear.
Other Names:
  • Butrans™

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The Number of Participants With Adverse Events as a Measure of Safety and Tolerability
Time Frame: 52 weeks
Safety was assessed using reports of adverse events, clinical laboratory results, findings from physical examinations, and vital sign measurements.
52 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Purdue Pharma LP

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2004

Primary Completion (Actual)

August 1, 2005

Study Completion (Actual)

August 1, 2005

Study Registration Dates

First Submitted

June 1, 2010

First Submitted That Met QC Criteria

June 1, 2010

First Posted (Estimate)

June 2, 2010

Study Record Updates

Last Update Posted (Estimate)

September 10, 2012

Last Update Submitted That Met QC Criteria

September 5, 2012

Last Verified

September 1, 2012

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • BUP3019S

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Osteoarthritis

Clinical Trials on Buprenorphine transdermal patch

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe